Amneal Pharmaceuticals (AMRX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue rose 13% year-over-year to $702M, driven by new product launches and growth across Generics, Specialty, and AvKARE segments.

• Adjusted EBITDA increased 2% to $158M, while GAAP net loss was $0.2M due to higher R&D, interest, and legal expenses.

• Launched CREXONT® for Parkinson's disease, expanded biosimilar portfolio, and entered a strategic partnership with Metsera for obesity/metabolic therapies.

• Significant legal charge of $94.9M in 2024 related to opioid litigation settlement.

• Affirmed full-year 2024 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Financial highlights

• Q3 2024 net revenue: $702M (+13% YoY); adjusted EBITDA: $158M (+2% YoY); adjusted diluted EPS: $0.16 (down from $0.19); GAAP net loss: $0.2M.

• Nine months ended September 30, 2024: net revenue $2.06B (+16.1% YoY); adjusted EBITDA $472M (+13.5% YoY); net loss $85.8M.

• Gross margin improved to 44% (non-GAAP) and 38.4% (GAAP); operating cash flow for nine months: $177M.

• Total debt at September 30, 2024: $2.5B; cash and equivalents: $74M.

• $127M gross debt paid down year-to-date.

Outlook and guidance

• Affirmed 2024 full-year guidance: net revenue $2.70–$2.80B, adjusted EBITDA $610–$630M, adjusted EPS $0.57–$0.63, capex $60–$70M.

• Operating cash flow expected at $280–$320M; guidance excludes one-time items.

• Targeting net leverage below 4x in 2025 and below 3x thereafter.

• Sufficient liquidity for the next 12 months, with $455.2M available under the main credit facility.

• Inflation expected to increase costs by $10–$15M in 2024.